Inventiva to Present Two Studies on Lanifibranor at EASL Congress 2026
Inventiva, a biopharmaceutical company specializing in the development of oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), announces the presentation of two abstracts at the annual European Association for the Study of the Liver (EASL Congress 2026), which will be held from May 27 to May 30, 2026, in Barcelona.
Two Poster Presentations on the Effects of Lanifibranor
The first abstract, titled 'Lanifibranor-induced improvements in histological parameters and cardiometabolic markers in MASH are independent of weight change and closely associated with adiponectin induction' (number FRI-189), will be presented as a poster on May 29, 2026. It is authored by Mary E Rinella, Guillaume Wettstein, Philippe Huot-Marchand, Jason Campagna, Sven Francque, and Manal F. Abdelmalek. The second abstract, 'Ultrastructural assessment of liver sinusoidal endothelial cell capillarisation in metabolic-dysfunction associated steatotic liver disease and its modulation by lanifibranor' (number SAT-117-YI), will also be presented as a poster on May 30, 2026. This presentation includes fourteen authors, among them Guillaume Wettstein and Sven M. Francque.
Lanifibranor, a Pan-PPAR Agonist in Clinical Development
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Lanifibranor is a small molecule administered orally designed to activate all three isoforms of PPAR (peroxisome proliferators). It induces anti-fibrotic, anti-inflammatory effects as well as positive vascular and metabolic changes. Inventiva believes that its moderate and balanced pan-PPAR modulator profile contributes to the good safety and tolerance profile observed in clinical trials and preclinical studies. The U.S. FDA has granted 'Breakthrough Therapy' and 'Fast Track' statuses to lanifibranor for the treatment of MASH. The drug candidate is currently being evaluated in the pivotal Phase 3 NATiV3 clinical study for the treatment of adult patients with MASH. Inventiva will also be present at the congress at booth number 35.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
